Status:
Recruiting
Disease Site:
Ovarian Fallopian Tube or Primary Peritoneal
Phase:
Phase II
Official Title:
GOG-3086 (STRO-002-GM3): Phase II Open-Label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin in Relapsed Platinum-Resistant Epithelial Ovarian Cancer Expressing FOLR1
NCT ID:
NCT#05870748
Link to Full Details:
Description:
A Phase 2 study to investigate the efficacy and safety of luveltamab tazevibulin in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Eligibility:
Female – 18 years and older
Inclusion Criteria:
- High-grade serous
- FOLR1 expression per central lab testing (results in 10 business days)
- Platinum resistant disease, total of 1-3 prior regimens
- One line of platinum-based tx must have had a CR or PR and then progressed more than 3 moths and less than/equal to 6 months after the last dose of platinum
- 2-3 prior lines of platinum tx must have progressed less than/equal to 6 months after the last dose of platinum
- Previous bevacizumab required, unless documented contraindication
Exclusion Criteria:
- Clear cell, mucinous, endometrioid, sarcomatous and mixed histology
- Primary refractory disease